
    
      Sixty-four subjects are planned to be studied in eight cohorts in this first-in human trial.
      Eight subjects will be allocated to the to eight dose levels. The entire observation period
      comprise 28 days starting with a 96 hours in-house stay, where discharge is planned for Day
      5, followed by five outpatient visits and an End of Trial Visit at Day 28. A blinded
      evaluation of each cohort will be performed by a Trial Safety Group to determine whether the
      trial will progress to the next dose level based on the stopping rules specified in protocol.
    
  